A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management

Health Technology Assessment

Volumn 12, Issue 3, 2008, Pages

  Thornton, J ^a   Ashcroft, D ^a   O'Neill, T ^a   Elliott, R ^a   Adams, J ^a   Roberts, C ^a   Rooney, M ^b   Symmons, D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

'POSTURE'; 22 OXACALCITRIOL; 25 HYDROXYVITAMIN D; ADCAL; ADCAL D3; ALENDRONIC ACID; ALFACALCIDOL; ALFAD; BISPHOSPHONIC ACID DERIVATIVE; CACIT; CACIT D3; CAL CITRATE; CAL LAC; CALCEOS; CALCICHEW; CALCICHEW D3 FORTE; CALCIFEDIOL; CALCITRIOL; CALCIUM; CALCIUM 500; CALCIUM CARBONATE; CALCIUM CHLORIDE; CALCIUM GLUBIONATE; CALCIUM LACTATE; CALFOVIT D3; CALPHRON; CALTRATE PLUS; CITRATE CALCIUM; CLODRONIC ACID; COLECALCIFEROL; DELTA D; DHT; DIHYDROTACHYSTEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; ETIDRONIC ACID; GLUCONATE CALCIUM; HALIBORANGE CALCIUM PLUS VITAMIN D; IBUPROFEN; OLPADRONIC ACID; ONDANSETRON; OSTEOCARE; OYSTER CALCIUM; PAMIDRONIC ACID; PARACETAMOL; PARICALCITOL; PHOS EX; PLACEBO; POROSIS D; PRELIEF; RISEDRONIC ACID; ROCATROL; SPHP; SUPER CITRACAL; TACHYROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE PAIN; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHILD; CHILD CARE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEHYDRATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; EFFECT SIZE; ELECTROLYTE BLOOD LEVEL; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL IRRITATION; HEALTH CARE COST; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCIURIA; HYPERTHERMIA; HYPOCALCEMIA; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LONG TERM CARE; LYMPHOCYTE COUNT; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; REVIEW; RIGOR; RISK FACTOR; SHORT COURSE THERAPY; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING; ADOLESCENT; ADULT; AGED; DISEASE MANAGEMENT; ECONOMICS; FEMALE; FRACTURE; MALE; MIDDLE AGED; PHOTON ABSORPTIOMETRY; RISK ASSESSMENT; TIME;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; AGED; ARTHRITIS, JUVENILE; CALCIUM; CHILD; DIPHOSPHONATES; DISEASE MANAGEMENT; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VITAMIN D;

EID: 42149177684     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta12030     Document Type: Review

References (327)

1. White PH. Clinical features of juvenile rheumatoid arthritis, In Hochberg MC, editor. Rheumatology, Edinburgh: Mosby; 2003. pp. 959-74.
2. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25:1991-4.
3. Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995; 22:1566-9.
4. Symmons DP, Jones M, Osborne J, Sills J, Southwood TR, Woo P. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol1996; 23:1975-80.
5. Thompson W, Silman AJ. Juvenile idiopathic arthritis. In: Silman AJ, Hochberg MC, Cooper C, editors. Epidemiology of the rheumatic diseases. Oxford: Oxford University Press; 2001. pp. 72-84.
6. European League Against Rheumatism. Nomenclature and classification of arthritis in children. Basel: National Zeitung; 1977.
7. Brewer EJ Jr, Bass J, Baum J, Cassidy JT, Fink C, Jacobs J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of the Arthritis Foundation. Arthritis Rheum 1977;20:195-9.
8. Gare BA. Epidemiology. Bailliere's Clin Rheumatol 1998; 12:191-208.
9. Grom AA, Glass DN. Etiology and pathogenesis of juvenile rheumatoid arthritis. In Hochberg MC, editor. Rheumatology. Edinburgh: Mosby; 2003. pp. 995-1001.
10. Ravelli A, Martini A. Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006;24: S105-10.
11. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003;88:197-200.
12. Murray KJ, Lovell DJ. Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002;16:361-78.
13. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94.
14. Zak M, Hassager C, Lovell DJ, Nielsen S, Henderson CJ, Pedersen FK. Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross-sectional long-term followup study. Arthritis Rheum 1999;42:790-8.
15. French AR, Mason T, Nelson AM, Crowson CS, O'Fallon WM, Khosla S, et al. Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population based study. J Rheumatol 2002;29: 1065-70.
16. Haugen M, Lien G, Flato B, Kvammen J, Vinje O, Sorskaar D, et al. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. Arthritis Rheum 2000; 43:1504-10.
17. Kotaniemi A, Savolainen A, Kroger H, Kautiainen H, Isomaki H. Weight-bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scand J Rheumatol 1999;29:19-26.
18. Rooney M, Davies UM, Reeve J, Preece M, Ansell BM, Woo PM. Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol 2000; 27:1073-81.
19. Perez MD, Abrams SA, Loddeke L, Shypailo R, Ellis KJ. Effects of rheumatic disease and corticosteroid treatment on calcium metabolism and bone density in children assessed one year after diagnosis, using stable isotopes and dual energy x-ray absorptiometry. J Rheumatol 2000; 58:38-43.
20. Brik R, Keidar Z, Schapira D, Israel O. Bone mineral density and turnover in children with systemic juvenile chronic arthritis. J Rheumatol 1998;25:990-2.
21. Henderson CJ, Specker BL, Sierra RI, Campaigne BN, Lovell DJ, Total-body bone mineral content in non-corticosteroid-treated postpubertal females with juvenile rheumatoid arthritis: frequency of osteopenia and contributing factors. Arthritis Rheum 2000;43:531-40.
22. Burnham JM, Shults J, Weinstein R, Lewis JD, Leonard MB. Childhood onset arthritis is associated with an increased risk of fracture: a population based study using the General Practice Research Database. Ann Rheum Dis 2006;65: 1074-9.
23. Weinstein RS. True strength. J Bone Miner Res 2000; 15:621-5.
24. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
25. Kanis JA. Diagnosis of osteoporosis. Osteoporos Int 1997;7 Suppl 3:S108-16.
26. Clark EM, Tobias JH, Ness AR. Association between bone density and fractures in children: a systematic review and meta-analysis. Pediatrics 2006;117:e291-7.
27. Goulding A, Jones IE, Taylor RW, Manning PJ, Williams SM. More broken bones: a 4-year double cohort study of young girls with and without distal forearm fractures. J Bone Miner Res 2000;15: 2011-18.
28. Stevenson M, Lloyd JM, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoparosis. Health Technol Assess 2005;9(22).
29. Srivastava T, Alon US, The role of bisphosphonates in diseases of childhood. Eur J Pediatr 2003;162:735-51.
30. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998;2(14).
31. Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child 2001;84:205-11.
32. Duffy CM. Measurement of health status, functional status, and quality of life in children with juvenile-idiopathic arthritis: clinical science for the pediatrician. Pediatr Clin North-Am 2005;52:359-72.
33. Zulian F. Outcome measures and medical progress: why outcome measures are needed in childhood arthritis. Cur Rheumatol Rep 2003; 5: 463-70.
34. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9.
35. Lam C., Noung N, Marwaha J, McLimont M, Feldman BM. Revised versions of the Childhood Health Assessment Questionnaire (CHAQ) are more sensitive and suffer less from a ceiling effect. Arthritis Rheum 2004; 51:881-9.
36. Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and tire Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001;19:S1-9.
37. Thastum M, Herlin T, Zachariae R. Relationship of pain-coping strategies and pain-specific beliefs to pain experience in children with juvenile idiopathic arthritis. Arthritis Rheum 2005;53: 178-84.
38. Sawyer MG, Whitham JN, Roberton DM, Taplin JE, Varni JW, Baghurst PA. The relationship between health-related quality of life, pain and coping strategies in juvenile idiopathic arthritis. Rheumatology (Oxford) 2004;43:325-30.
39. Sallfors C, Hallberg LR, Fasth A. Gender and age differences in pain, coping and health status among children with chronic arthritis. Clin Exp Rheumatol 2003;21:785-93.
40. Bekkering WP, ten Cate R, Suijlekom-Smit LW, Mul D, van der Velde EA, van den Ende CH. The relationship between impairments in joint function and disabilities in independent function in children with systemic juvenile idiopathic arthritis. J Rheumatol 2001; 28:1099-105.
41. Takken T, Van der NJ, Helders PJ. Relationship between functional ability and physical fitness in juvenile idiopathic arthritis patients. Scand J Rheumatol 2003;32:174-8.
42. Wessel J, Kaup C, Fan J, Ehalt R, Ellsworth J, Speer C, et al. Isometric strength measurements in children with arthritis: reliability and relation to function. Arthritis Care Res 1999; 12:238-46.
43. Fan JS, Wessel J, Ellstvorth J. The relationship between strength and function in females with juvenile rheumatoid Arthritis. J Rheumatol. 1998;25: 1399-405.
44. Gare BA, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. II. Outcome. J Rheumatol 1995; 22:308-19.
45. Ruperto N, Levinson JE, Ravelli A, Shear ES, Link TB, Murray K, et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol. 1997;24:945-51.
46. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989-99.
47. Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al. Early predictors of poor functional outcome in systemic-onset-juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000;43:2402-9.
48. Selvaag AM, Lien G, Sorskaar D, Vinje O, Forre O, Flato B. Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study. J Rheumatol 2005;32:1122-30.
49. Pouchot J, Ecosse E, Coste J, Guillemin F, French Quality of Life Study Group, Paediatric Rheumatology International Trials Organisation. Validity of the childhood health assessment questionnaire is independent of age in juvenile idiopathic arthritis. Arthritis Rheum 2004; 51:519-26.
50. Ruperto N, Ravelli A, Migliavacca D, Viola S, Pistorio A, Duarte C, et al. Responsiveness of clinical measures in children with oligoarticular juvenile chronic arthritis. J Rheumatol 1999; 26: 1827-30.
51. Ruperto N, Ravelli A, Palcini F, Lepore L, Buoncompagni A, Gerloni V, et al. Responsiveness of outcome measures in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Rheumatology (Oxford) 1999;38:176-80.
52. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
53. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26.
54. Takken T, Van der NJ, Kuis W, Helders PJ. Aquatic fitness training for children with juvenile idiopathic arthritis. Rheumatology (Oxford) 2003;42:1408-14.
55. Wright FV, Law M, Crombie V, Goldsmith CH, Dent P. Development of a self-report functional status index for juvenile rheumatoid arthritis. J Rheumatol 1994;21:536-44.
56. Wright FV, Kimber JL, Law M, Goldsmith CH, Crombie V, Dent P. The Juvenile Arthritis Functional Status Index (JASI): a validation study. J Rheumatol 1996;23:1066-79.
57. Lovell DJ, Howe S, Shear E, Hartner S, McGirr G, Schulte M, et al. Development of a disability measurement tool for juvenile rheumatoid arthritis. The Juvenile Arthritis Functional Assessment Scale. Arthritis Rheum 1989;32:1390-5.
58. Howe S, Levinson J, Shear E, Hartner S, McGirr G, Schulte M, et al. Development of a disability measurement tool for juvenile rheumatoid arthritis. The Juvenile Arthritis Functional Assessment Report for Children and their Parents. Arthritis Rheum 1991; 34:873-80.
59. Coulton CJ, Zborowsky E, Lipton J, Newman AJ. Assessment of the reliability and validity of the arthritis impact measurement scales for children with juvenile arthritis. Arthritis Rheum 1987;30: 819-24.
60. Duffy CM, Arsenault L, Duffy KN, Paquin JD, Strawczynski H. The Juvenile Arthritis Quality of Life Questionnaire - development of a new responsive index for juvenile rheumatoid arthritis and juvenile spondyloarthritides. J Rheumatol 1997;24:738-46.
61. Nugent J, Ruperto N, Grainger J, Machado C, Sawhney S, Baildam E, et al. The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19:S163-7.
62. Selvaag, AM, Flato B, Lien G, Sorskaar D, Vinje O, Forre O. Measuring health status in early juvenile idiopathic arthritis: determinants and responsiveness of the child health questionnaire. J Rheumatol. 2003;30:1602-10.
63. Varni JW, Seid M, Smith KT, Burwinkle T, Brown J, Szer IS. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 2002;46:714-25.
64. Feldman BM, Grundland B, McCullough L, Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol 2000; 27:226-33.
65. Hennessy S, Kind P. Measuring health status in children: developing and testing a child-friendly version of the EQ-5D. In: Kind P, Macan S, editors. Proceedings of the 19th Plenary Meeting of the EuroQol Group, September 13-14, 2002, University of York: Centre for Health Economics. pp. 291-310.
66. Petersen C, Schmidt S, Power M, Bullinger M, The DISABKIDS Group. Development and pilot-testing of a health-related quality of life chronic generic module for children and adolescents with chronic health conditions: a European perspective. Qual Life Res 2005; 14:1065-77.
67. Celiker R, Bal S, Bakkaloglu A, Ozaydin E, Coskun T, Cetin A, et al. Factors playing a role in the development of decreased bone mineral density in juvenile chronic arthritis. Rheumatol Int 2003; 23:127-9.
68. Mul D, Suijlekom-Smit LW, ten Cate R, Bekkering WP, de Muinck Keizer-Schrama SM. Bone mineral density and body composition and influencing factors in children with rheumatic diseases treated with corticosteroids. J Pediatr Endocrinol 2002;15:187-92.
69. Davies JH, Evans BAJ, Gregory JW. Bone mass acquisition in healthy children. Arch Dis Child 2005;90:373-8.
70. Cameron JR, Sorensen J. Measurement of bone mineral in vivo: an improved method. Science 1963;142:230-2.
71. Sorenson JA, Cameron JR. A reliable in vivo measurement of bone-mineral content. J Bone Joint Surg Am 1967;49:481-97.
72. Henderson RC. The correlation between dual-energy X-ray absorptiometry measures of bone density in the proximal femur and lumbar spine of children. Skeletal Radiol 1997;26:544-7.
73. Shore RM, Langman CB, Donovan JM, Conway JJ, Poznanski AK. Bone mineral disorders in children: evaluation with dual x-ray absorptiometry. Radiology 1995;196:535-40.
74. Lee WT, Cheung AY, Lau J, Lee SK, Qin L, Cheng JC. Bone densitometry: which skeletal sites are best predicted by bone mass determinants? J Bone Miner Metab 2004;22:447-55.
75. Hernandez-Prado B, Lazcano-Pbnce E, Cruz-Valdez A, Diaz R, Tamayo J, Hernandez-Avila M. Validity of bone mineral density measurements in distal sites as an indicator of total bone mineral density in a group of pre-adolescent and adolescent women. Arch Med Res 2002; 33:33-9.
76. National Osteoporosis Society. A Practical guide to bone densitometrv in children. Bath: National Osteoporosis Society; 2004.
77. Leonard MB, Propert KJ, Zemel BS, Stallings VA, Feldman HI. Discrepancies in pediatric bone mineral density reference data: potential for misdiagnosis of osteoprenia. J Pediatr 1999; 135:182-8.
78. Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr 2004;144:253-7.
79. Hannan, WJ, Cowen SJ, Wrate RM, Barton J. Improved prediction of bone mineral content and density. Arch Dis Child 1995;72:147-9.
80. Kelly TL, Specker BL, Binkley T, Zemel BS, Leonard MB, Kalkwarf HJ, et al. Pediatric BMD reference database for US white children. Bone 2005;36:S30.
81. Fewtrell MS, British Paediatric and Adolescent Bone Group. Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Arch Dis Child 2003;88:795-8.
82. Katzman DK, Bachrach LK, Carter DR, Marcus R. Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab 1991;73:1332-9.
83. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992;7: 137-45.
84. Kroger H, Kotaniemi A, Vainio P, Alhava E. Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry. Bone Miner 1992;17:75-85.
85. Prentice A, Parsons TJ, Cole TJ. Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr 1994;60:837-42.
86. Warner JT, Cowan FJ, Dunstan FDJ, Evans WD, Webb DKH, Gregory JW. Measured and predicted bone mineral content in healthy boys and girls aged 6-18 years: adjustment for body size and puberty. Acta Paediatr 1998;87:244-9.
87. Molgaard C, Thomsen BL, Prentice A, Cole TJ, Michaelsen KF. Whole body bone mineral content in healthy children and adolescents. Arch Dis Child 1997;76:9-15.
88. Fewtrell MS, Gordon I, Biassoni L, Cole TJ. Dual X-ray absorptiometry (DXA) of the lumbar spine in a clinical paediatric setting: Does the method of size-adjustment matter? Bone 2005;37:413-19.
89. Kalender WA, Felsenberg D, Genant HK, Fischer M, Dequeker J, Reeve J. The European Spine Phantom - a tool for standardization and quality control in spinal bone mineral measurements by DXA and QCT. Eur J Radiol 1995;20:83-92.
90. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M. Engelke K, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994; 9:1503-14.
91. Glastre C, Braillon P, David L, Cochat P, Meunier PJ, Delmas PD. Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 1990;70:1330-3.
92. Ponder SW, McCormick DP, Fawcett HD, Palmer JL, McKernan MG, Brouhard BH. Spinal bone mineral density in children aged 5.00 through 11.99 years. Am J Dis Child 1990;144:1346-8.
93. Southard RN, Morris JD, Mahan JD, Hayes JR, Torch MA, Sommer A, et al. Bone mass in healthy children: measurement with quantitative DXA. Radiology 1991;179:735-8.
94. Faulkner RA, Bailey DA, Drinkwater DT, Wilkinson AA, Houston CS, McKay HA. Regional and total body bone mineral content, bone mineral density, and total body tissue composition in children 8-16 years of age. Calcif Tissue Int 1993;53:7-12.
95. Zanchetta JR, Plotkin H, Filgueira MLA. Bone mass in children: normative values for the 2-20-year-old population. Bone 1995; 16:S393-9.
96. Ogle GD, Allen JR, Humphries IR, Lu PW, Briody JN, Morley K, et al. Body, composition assessment by dual-energy x-ray absorptiometry in subjects aged 4-26 y. Am J Clin Nutr 1995;61: 746-53.
97. Faulkner RA, Bailey DA, Drinkwater DT, McKay HA, Arnold C, Wilkinson AA. Bone densitometry in Canadian children 8-17 years of age. Calcif Tissue Int 1996;59:344-51.
98. Boot AM, de Ridder MAJ, Pols HAP, Krenning EP, de Muinck Keizer-Schrama S. Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin.Endocrinol Metab 1997;82:57-62.
99. Maynard LM, Guo SS, Chumlea WC, Roche AF, Wisemandle WA, Zeller CM, et al. Total-body and regional bone mineral content and Areal bone mineral density in children aged 8-18 y: the Fels Longitudinal Study. Am J Clin Nutr 1998;68: 1111-17.
100. Molgaard C, Thomsen BL, Michaelsen KF. Influence of weight, age and puberty on bone size and bone mineral content in healthy children and adolescents. Acta Paediatr 1998;87:494-9.
101. Lotborn M, Bratteby LE, Samuelson G, Ljunghall S, Sjostrom L. Whole-body bone mineral measurements in 15-year-old Swedish adolescents. Osteoporos Int 1999;9:106-14.
102. Horlick M, Thornton J, Wang J, Levine LS, Fedun B, Pierson RN Jr. Bone mineral in prepubertal children: gender and athnicity. J Bone Miner Res 2000;15:1393-7.
103. Ellis KJ, Shypailo RJ, Hardin DS, Perez MD, Motil KJ, Wong WW, et al. Z score prediction model for assessment of bone mineral content in pediatric diseases. J Bone Miner Res 2001;16: 1658-64.
104. Henderson RC, Lark RK, Newman JE, Kecskemthy H, Fung EB, Renner JB, et al. Pediatric reference data for dual X-ray absorptiometric measures of normal bone density, in the distal femur. Am J Roentgenol 2002;178: 439-43.
105. Van der Sluis, I, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM. Reference data for bone density and body composition measured with dual energy x-ray absorptiometry in white children and young adults. Arch Dis Child 2002;87:341-7.
106. Binkley TL, Specker BL, Wittig TA. Centile curves for bone densitometry measurements in healthy males and females aged 5-22 yr. J Clin Densitom 2002;5:343-53.
107. Arabi A, Nabulsi M, Maalouf J, Choucair M, Khalife H, Vieth R, et al. Bone mineral density by age, gender, pubertal stages, and socioeconomic status in healthy Lebanese children and adolescents. Bone 2004;35:1169-79.
108. Henry YM, Fatayerji D, Eastell R. Attainment of peak bone mass at the lumbar spine, femoral neck and radius in men and women: relative contributions of bone size and volumetric bone mineral density. Osteoporos Int 2004;15:263-73.
109. Cromer BA, Binkovitz L, Ziegler J, Hafvey R, Debanne SM. Reference values for bone mineral density in 12- to 18-year-old girls categorized by weight, race, and age. Pediatr Radiol 2004;34: 787-92.
110. Willing MC, Torner JC, Burns TL, Janz KF, Marshall TA, Gilmore J, et al. Percentile distributions of bone measurements in Iowa children: the Iowa bone development study. J Clin Densiton. 2005; 8:39-47.
111. Lu, PW, Briody JN, Ogle GD, Morley K, Humphries IRJ, Allen J, et al. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994;9: 1451-8.
112. Sabatier JP, Guaydier-Souquieres G, Benmalek, A, Marcelli C. Evolution of lumbar bone mineral content during adolescence and adulthood: a longitudinal study in 395 healthy females 10-24 years of age and 206 premenopausal women. Osteoporos Int 1999;9:476-82.
113. Nguyen TV, Maynard LM, Towne B, Roche AF, Wisemandle W, Li J, et al. Sex differences in bone mass acquisition during growth: the Fels Longitudinal Study. J Clin Densitom 2001;4:147-57.
114. Lu PW, Cowell CT, LLoyd-Jones SA, Briody JN, Howman-Giles R. Volumetric bone mineral density in normal subjects, aged 5-27 years. J Clin Endocrinol Metab 1996;81:1586-90.
115. Fulkerson JA, Himes JH, French SA, Jensen S, Petit MA, Stewart C, et al. Bone outcomes and technic measurement issues of bone health among children and adolescents: considerations for nutrition and physical activity intervention trials. Osteoporos Int 2004; 15:929-41.
116. van Rijn RR, Van DS, I, Link TM, Grampp S, Guglielmi G, Imhof H. et al. Bone densitometry in children: a critical appraisal. Eur Radiol 2003;13: 700-10.
117. Kalender WA. Effective dose values in bone mineral measurements by photon absorptiometry and computed tomography. Osteoporos Int 1992; 2:82-7.
118. Faulkner KG. Investigations of bone: densitometry. In: Hochberg MC, Silman AS, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Edinburgh: Mosby; 2003. pp. 2067-74.
119. Gilsanz V, Gibbens DT, Roe TF, Carlson M, Senac MO, Boechat MI, et al. Vertebral bone density in children: effect of puberty. Radiology 1988;166: 847-50.
120. Gilsanz V, Roe TF, Mora S, Costin G, Goodman WG. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med 1991;325:1597-600.
121. Fujita T, Fujii Y, Goto B. Measurement of forearm bone in children by peripheral computed tomography. Calcif Tissue Int 1999; 64:34-9.
122. Neu CM, Manz F, Rauch F, Merkel A, Schoenau E. Bone densities and bone size at the distal radius in healthy children and adolescents: a study using peripheral quantitative computed tomography. Bone 2001; 28:227-32.
123. Moyer-Mileur L, Xie B, Ball S, Bainbridge C, Stadler D, Jee WS. Predictors of bone mass by peripheral quantitative computed tomography in early adolescent girls. J Clin Densitom 2001;4:313-23.
124. Binkley TL, Specker BL. pQCT measurement of bone parameters in young children: validation of technique. J Clin Densitom 2000:3:9-14.
125. Volta C, Bagni B, Iughetti L, Rossi M, Corazzari T, Bagni I, et al. Bone mass evaluated by calcaneous ultrasound and radial peripheral computed tomography in 726 youngsters. Acta Paediatr 2004;93:747-51.
126. Loro ML, Sayre J, Roe TF, Goran MI, Kaufman FR, Gilsanz V. Early identification of children predisposed to low peak bone mass and osteoporosis later in life. J Clin Endocrinol Metab 2000; 85:3908-18.
127. Mora S, Gilsanz V. Bone densitometry in children. In: Genant HK, Guglielmi G, Jergas M, editors. Bone densitometry and osteoporosis. Berlin: Springer; 1998. pp. 489-502.
128. Khaw KT, Reeve J, Luben R, Bingham S, Welch A, Wareham N, et al. Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study. Lancet 2004;363: 197-202.
129. Pluijm SM, Graafmans WC, Bouter LM, Lips P. Ultrasound measurements for the prediction of osteoporotic fractures in elderly people. Osteoporos Int 1999;9:550-6.
130. Stewart A, Torgerson DJ, Reid DM. Prediction of fractures in perimenopausal women: a comparison of dual energy x-ray absorptiometry and broadband ultrasound attenuation. Ann Rheum Dis 1996:55:140-2.
131. Schonau E, Radermacher A, Wentzlik U, Klein K, Michalk D. The determination of ultrasound velocity in the os calcis, thumb and patella during Childhood. Eur J Pediatr 1994;153:252-6.
132. Mughal MZ, Langton CM, Utretch G, Morrison J, Specker BL. Comparison between broad-band ultrasound attenuation of the calcaneum and total body bone mineral density in children. Acta Paediatr 1996; 85:663-5.
133. Mughal MZ, Ward K, Qayyum N, Langton CM. Assessment of bone status using the contact ultrasound bone analyser. Arch Dis Child 1997; 76: 535-6.
134. Sundberg M, Gardsell Johnell O, Ornstein E, Sernbo I. Comparison of quantitative ultrasound measurements in calcaneus with DXA and SXA at other skeletal sites: a population-based study on 280 children aged 11-16 years. Osteoporos Int 1998;8:410-17.
135. Lum CK, Wang MC, Moore E, Wilson DM, Marcus R, Bachrach LK. A comparison of calcaneus ultrasound and dual X-ray absorptiometry in healthy North American youths and young adults. J Clin Densitom 1999; 2:403-11.
136. Sawyer A, Moore S, Fielding KT, Nix DA, Kiratli J, Bachrach LK. Calcaneus ultrasound measurements in a convenience sample of healthy youth. J Clin Densitom 2001;4:111-20.
137. Wunsche K, Wunsche B, Fahnrich H, Mentzel HJ, Vogt S, Abendroth K, et al. Ultrasound bone densitometry of the os calcis in children and adolescents. Calcif Tissue Int 2000;67:349-55.
138. van den Bergh JP, Noordam C, Ozyilmaz A, Hermus AR, Smals AG, Otten BJ. Calcaneal ultrasound imaging in healthy children and adolescents: relation of the ultrasound parameters BUA and SOS to age, body weight, height, foot dimensions and pubertal stage. Osteoporos Int 2000; 11:967-76.
139. Lequin MH, Hop WC, van Rijn RR, Bukkems MC, Verhaak LL, Robben SG, et al. Comparison between quantitative calcaneal and tibial ultrasound in a Dutch Caucasian pediatric and adolescent population. J Clin Densitom 2001;4: 137-46.
140. Ikeda Y, Iki M, Morita A, Aihara H, Kagamimori S, Kagawa Y, et al. Ultrasound bone densitometry of the Calcaneus, determined with Sahara, in healthy Japanese adolescents: Japanese Population-based Osteoporosis (JPOS) Study. J Bone Miner Metab 2004;22:248-53.
141. Micklesfield LK, Zielonka EA, Charlton KE, Katzenellenbogen L, Harkins J, Lambert EV. Ultrasound bone measurements in pre-adolescent girls: interaction between ethnicity and lifestyle factors. Acta Paediatr 2004;93:752-8.
142. Lequin MH, van Rijn RR, Robben SG, Hop WC, Dijkhuis S, Fijten MM, et al. Evaluation of shortterm precision for tibial ultrasonometry. Calcif Tissue Int 1999;64:24-7.
143. van Rijn RR, Van DS, I, Lequin MH, Robben SG, de Muinck Keizer-Schrama SM, Hop WC, et al. Tibial quantitative ultrasound versus whole-body and lumbar spine DXA in a Dutch pediatric and adolescent population. Invest Radiol 2000;35: 548-52.
144. Lequin MH, van Rijn RR, Robben SG, Hop WC, van Kuijk C. Normal values for tibial quantitative ultrasonometry in caucasian children and adolescents (aged 6 to 19 years). Calcif Tissue Int 2000; 67:101-5.
145. Lappe JM, Recker RR, Malleck MK, Stegman MR, Packard PP, Heaney RP. Patellar ultrasound transmission velocity in healthy children and adolescents. Bone 1995;16:251S-6S.
146. Lappe JM, Recker RR, Weidenbusch D. Influence of activity level on patellar ultrasound transmission velocity in children. Osteoporos Int 1998;8:39-46.
147. Halaba Z, Pluskiewicz W. The assessment of development of bone mass in children by quantitative ultrasound through the proximal phalanxes of the hand. Ultrasound Med Biol 1997;23:1331-5.
148. Baroncelli GI, Federico G, Bertelloni S, De Terlizzi F, Cadossi R, Saggese G. Bone quality assessment by quantitative ultrasound of proximal phalanxes of the hand in healthy subjects aged 3-21 years. Pediatr Res 2001;49:713-18.
149. Daly RM, Rich PA, Klein R. Influence of high impact loading on ultrasound bone measurements in children: a cross-sectional report. Calcif Tissue Int 1997;60:401-4.
150. Lehtonen-Veromaa M, Mottonen T, Nuotio I, Heinonen OJ, Viikari J. Influence of physical activity on ultrasound and dual-energy X-ray absorptiometry bone measurements in peripubertal girls: a cross-sectional study. Calcif Tissue Int 2000;66:248-54.
151. Lappe JM, Stegman M, Davies KM, Barber S, Recker RR. A prospective study of quantitative ultrasound in children and adolescents. J Clin Densitom 2000;3:167-75.
152. Brukx LJ, Waelkens JJ. Evaluation of the usefulness of a quantitative ultrasound device in screening of bone mineral density in children. Ann Hum Biol 2003;30:304-15.
153. Barnett E, Nordin BEC. The radiological diagnosis of osteoporosis: a new approach. Clin Radiol 2005;11:166-74.
154. Garn SM. The earlier gain and later loss of cortical bone. In: Garn SM, editor. Nutritional perspective. Springfield, IL: Charles C Thomas; 1970. p. 146.
155. Meema HE. Improved vertebral fracture threshold in postmenopausal osteoporosis by radiogrametric measurements: its usefulness in selection for preventive therapy. J Bone Miner Res 1991;6:9-14.
156. Meema HE, Meema S. Postmenopausal osteoporosis: simple screening method for diagnosis before structural failure. Radiology 1987; 164:405-10.
157. Meema HE, Meindok H. Advantages of peripheral radiogrametry over dual-photon absorptiometry of the spine in the assessment of prevalence of osteoporotic vertebral fractures in women. J Bone Miner Res 1992;7:897-903.
158. Malich A, Freesmeyer MG, Mentzel HJ, Sauner D, Boettcher J, Petrovitch A, et al. Normative values of bone parameters of children and adolescents using digital computer-assisted radiogrammetry (DXR). J Clin Densitom 2003;6:103-11.
159. Henderson CJ, Cawkwell GD, Specker BL, Sierra RI, Wilmott RW, Campaigne BN, et al. Predictors of total body bone mineral density in non-corticosteroid- treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:1967-75.
160. Pereira RM, Corrente JE, Chahade WH, Yoshinari NH. Evaluation by dual X-ray absorptiometry (DXA) of bone mineral density in children with juvenile chronic arthritis. Clin Exp Rheumatol 1998; 16:495-501.
161. Chlebna-Sokol D, Brozik H, Bujnowski T, Biernacka M, Loba-Jakubowska E, Sikora A, et al. Significance of densitometry and biochemical tests in diagnosis of osteoporosis in children suffering from juvenile rheumatoid arthritis. Med Sci Monit 1999;5:720-5.
162. Njeh CF, Shaw N, Gardner-Medwin JM, Boivin CM, Southwood TR. Use of quantitative ultrasound to assess bone status in children with juvenile idiopathic arthritis: a pilot study. J Clin Densitom 2000; 3:251-60.
163. Fielding KT, Nix DA, Bachrach LK. Comparison of calcaneus ultrasound and dual X-ray absorptiometry in children at risk of osteopenia. J Clin Densitom 2003;6:7-15.
164. Lien G, Flato B, Haugen M, Vinje O, Sorskaar D, Dale K, et al. Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients. Arthritis Rheum 2003;48: 2214-23.
165. Hartman C, Shamir R, Eshach-Adiv O, Iosilevsky G, Brik R. Assessment of osteoporosis by quantitative ultrasound versus dual energy X-ray absorptiometry in children with chronic rheumatic diseases. J Rheumatol 2004;31:981-5.
166. Alsufyani KA, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Nadel H, et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005; 32:729-33.
167. Kotaniemi A, Savolainen A, Kautiainen H, Kroger H. Estimation of central osteopenia in children with chronic polyarthritis treated with glucocorticoids. Pediatrics 1993;91:1127-30.
168. Pepmueller PH, Cassidy JT, Allen SH, Hillman LS. Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 1996;39:746-57.
169. Lilleby V, Lien G, Frey FK, Haugen M, Flato B, Forre O. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum 2005;52:2051-9.
170. Kotaniemi A, Savolainen A, Kroger H, Kautiainen H, Isomaki H. Development of bone mineral density at the lumbar spine and femoral neck in juvenile chronic arthritis - a prospective one year followup study. J Rheumatol 1998;25: 2450-5.
171. Bianchi ML, Cimaz R, Galbiati E, Corona F, Cherubini R, Bardare M. Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis. Osteoporos Int 1999;10:20-5.
172. Falcini F, Bindi G, Ermini M, Galluzzi F, Poggi G, Rossi S, et al. Comparison of quantitative calcaneal, ultrasound and dual energy X-ray absorptiometry in the evaluation of osteoporotic risk in children with chronic rheumatic diseases. Calcif Tissue Int 2000; 67:19-23.
173. Stewart WA, Acott PD, Salisbury SR, Lang BA. Bone mineral density in juvenile dermatomyositis: assesment using dual x-ray absorptiometry. Arthritis Rheum 2003;48:2294-8.
174. Lien G, Selvaag AM, Flato B, Haugen M, Vinje O, Sorskaar D, et al. A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis. Arthritis Rheum 2005;52:833-40.
175. Bechtold S, Ripperger P, Bonfig W, Schmidt H, Bitterling H, Hafner R, et al. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. J Rheumatol 2004;31: 1407-12.
176. Kroger H, Vainio P, Nieminen J, Kotaniemi A. Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. Bone 1995;17:157-9.
177. Fredericks BJ, de Campo JI, Sephton R. McCredie DA. Computed tomographic assessment of vertebral bone mineral in childhood. Skeletal Radiol 1990;19:99-102.
178. Lettgen B, Neudorf U, Hosse R, Peters S. Reiners C. Bone density in children and adolescents with rheumatic disease. Preliminary results of selective measurement of trabecular and cortical bone by peripheral computed tomography. Klin Padiatr 1996;208:114-17.
179. Baroncelli GI, Federico G, Bertelloni S, Sodini F, De Terlizzi F, Cadossi R, et al. Assessment of bone quality by quantitative ultrasound of proximal phalanges of the hand and fracture rate in children and adolescents with bone and mineral disorders. Pediatr Res 2003;54:125-36.
180. Jaworski M, Lebiedowski M, Lorenc RS, Trempe J. Ultrasound bone measurement in pediatric subjects. Calcif Tissue Int 1995; 56:368-71.
181. van Rijn RR, Grootfaam DS, Lequin MH, Boot AM, Van Beek RD, Hop WCJ, et al. Digital radiogrammetry of the hand in a pediatric and adolescent Dutch Caucasian population: normative data and measurements in children with inflammatory bowel disease and juvenile chronic arthiritis. Calcif Tissue Int 2004;74:342-50.
182. Schoenau E, Rauch F. Biochemical measurements of bone metabolism in childhood and adolescence. Laboratoriums Medizin 2003:27:32-42.
183. Ziambaras K, Civitelli R. Biochemical markers of bone turnover. In Genant HK, Guglielmi G, Jergas M, editors. Bone densitometry and osteoporosis. Berlin: Springer; 1998. pp. 95-125.
184. Garnero P, Delmas PD. Investigation of bone: biochemical markers. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology.-Edinburgh: Mosby; 2003. 2043-57.
185. de Ridder CM, Delemarre-van de Waal HA. Clinical utility of markers of bone turnover in children and adolescents. Curr Opin Pediatr 1998;10:441-8.
186. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000;11:281-94.
187. Mora S, Pitukcheewanont P, Kaufman FR, Nelson JC, Gilsanz V. Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res 1999;14:1664-71.
188. Magnusson P, Hager A, Larsson L. Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. Pediatr Res 1995;38:955-61.
189. Isai K-S, Jang M-H, Hsu SHJ, Cheng W-C, Chang M-H. Bone alkaline phosphatase isoenzyme and carboxy-terminal propeptide of type-I procollagen in healthy Chinese girls and boys. Clin Chem 1999; 45:136-8.
190. Cioffi M, Molinari AM, Gazzerro P, Di Finizio B, Fratta M, Deufemia A, et al. Serum osteocalcin in 1634 healthy children. Clin Chem 1997;43:543-5.
191. Tommasi M, Bacciottini L, Benucci A, Brocchi A, Passeri A, Saracini D, et al. Serum biochemical markets of bone turnover in healthy infants and children. Int J Biol Markers 1996;11:159-64.
192. Johansen JS, Giwercman A, Hartwell D, Nielsen CT. Price PA, Christiansen C. et al. Serum bone G1a-protein as a marker of bone growth in children and adolescents: Correlation with age, height, serum insulin-like growth factor I, and serum testosterone. J Clin Endocrinol Metab 1988;67:273-8.
193. Blumsohn A, Hannon RA, Wrate R, Barton J, Al Dehaimi AW, Colwell A, et al. Biochemical markers of bone turnover in girls during puberty. Clin. Endocrinol (Oxf) 1994;40:663-70.
194. Saggese G, Bertelloni S, Baroncelli GI, Di Nero G. Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 1992;151:764-8.
195. Crofton PM, Wade JC, Taylor MR, Holland CV. Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren. Clin Chem 1997;43:1577-81.
196. Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook CG, Mowat AP. Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res 1991; 30:276-80.
197. Zanze M, Souberbielle JC, Kindermans C, Rossignol C, Garabedian M. Procollagen propeptide and pyridinium cross-links as markers of type I collagen turnover: sex- and age-related changes in healthy children. J Clin Endocrinol Metab 1997;82:2971-7.
198. Mora S, Prinster C, Proverbio MC, Bellini A, de Poli SC, Weber G, et al. Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty. Calcif Tissue Int 1998;63:369-74.
199. Weaver CM, Peacock M, Martin BR, McCabe GP, Zhao J, Smith DL, et al. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. J Bone Miner Res 1997; 12: 1714-20.
200. Rauch F, Schnabel D, Seibel MJ, Remer T, Stabrey A, Michalk D, et al. Urinary excretion of galactosyl-hydroxylysine is a marker of growth in children. J Clin Endocrinol Metab 1995;80: 1295-300.
201. Rauch F, Georg M, Stabrey A, Neu C, Blum WF, Remer T, et al. Collagen markers deoxypyridinoline and hydroxylysine glycosides: Pediatric reference data and use for growth prediction in growth hormone-deficient children. Clin Chem 2002;48: 315-22.
202. Lieuw AF, Sierra RI, Specker BL. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. J Bone Miner Res 1995; 10:849-53.
203. Husain SM, Mughal Z, Williams G, Ward K, Smith CS, Dutton J, et al. Urinary excretion of pyridinium crosslinks in healthy 4-10 year olds. Arch Dis Child 1999;80:370-3.
204. Marowska J, Kobylinska M, Lukaszkiewicz J, Talajko A, Rymkiewicz-Kluczynska B, Lorenc RS. Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents: normal values and clinical application. Bone 1996;19:669-77.
205. Rauch F, Schouau E, Woitge H, Remer T, Seibel M. Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children. Exp Clin Endocrinol 1994;102: 94-7.
206. Beardsworth LJ, Eyre DR, Dickson IR. Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res 1990;5:671-6.
207. Conti A, Ferrero S, Giambona S, Sartorio A. Urinary free deoxypyridinoline levels during childhood. J Endocrinol Invest 1998;21:318-22.
208. Shaw NJ, Dutton J, Fraser WD, Smith CS. Urinary pyridinoline and deoxypyridinoline excretion in children. Clin Endocrinol (Oxf) 1995;42:607-12.
209. Bollen A-M, Eyre DR. Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 1994;15:31-4.
210. Crofton PM, Evans N, Taylor MR, Holland CV. Serum CrossLaps: pediatric reference intervals from birth to 19 years of age. Clin Chem 2002;48: 671-3.
211. Briot K, Roux C. What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring? Best Pract Res Clin Rheumatol 2005;19:951-64.
212. Crofton PM, Kelnar CJ. Bone and collagen markers in paediatric practice. Int J Clin Pract 1998;52:557-65.
213. Reeve J, Loftus J, Hesp R, Ansell BM, Wright DJ, Woo PM. Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. J Rheumatol 1993;20:1189-95.
214. Polito C, Strano CG, Rea L, Alessio M, Iammarrone CS, Todisco N, et al. Reduced bone mineral content and normal serum osteocalcin in non-steroid-treated patients with juvenile rheumatoid arthritis. Ann Rheum Dis 1995;54: 193-6.
215. Bardare M, Bianchi ML, Furia M, Gandolini GG, Cohen E, Montesano A. Bone mineral metabolism in juvenile chronic arthritis: the influence of steroids. Clin Exp Rheumatol 1991;9:29-31.
216. Hillman L, Cassidy JT, Johnson L, Lee D, Allen SH. Vitamin D metabolism and bone mineralization in children with juvenile rheumatoid arthritis. J Pediatr 1994;124:910-16.
217. Falcini F, Ermini M, Bagnoli F. Bone turnover is reduced in children with juvenile rheumatoid arthritis. J Endocrinol Invest 1998; 21:31-6.
218. Pereira RM, Falco V, Corrente JE, Chahade WH, Yoshinari NH. Abnormalities in the biochemical markers of bone turnover in children with juvenile chronic arthritis. Clin Exp Rheumatol 1999; 17:251-5.
219. Bianchi ML, Bardare M, Caraceni MP, Cohen E, Falvella S, Borzani M, et al. Bone metabolism in juvenile rheumatoid arthritis. Bone Miner 1990;9: 153-62.
220. Reed A, Haugen M, Pachman EM, Langman CB. Abnormalities in serum-osteocalcin values in children with chronic rheumatic diseases. J Pediatr 1990;116:574-80.
221. Touati G, Ruiz J-C, Porquet D, Kindermans C, Prieur A-M, Czernichow P. Effects on bone metabolism of one year recombinant human growth hormone administration to children with juvenile chronic arthritis undergoing chronic steroid therapy. J Rheumatol 2000;27:1287-93.
222. Simon D, Prieur A-M, Czernichow P. Treatment of juvenile rheumatoid arthritis with growth hormone. Horm Res 2000;53:82-6.
223. Varonos S, Ansell BM, Reeve J. Vertebral collapse in juvenile chronic arthritis its relationship with glucocorticoid therapy. Calcif Tissue Int 1987;41: 75-8.
224. Elsasser U, Wilkins B, Hesp R, Thurnham DI, Reeve J, Ansell BM. Bone rarefaction and crush fractures in juvenile chronic arthritis. Arch Dis Child 1982;57:377-80.
225. Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005;115:e600-14.
226. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non randomised intervention studies. Health Technol Assess 2003;7(27).
227. Dalziel K, Round A, Stein K, Garside R, Castelnuovo E, Payne L. Do the findings of case series studies vary significantly according to methodological characteristis? Health Technol Assess 2005; 9(2).
228. Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning Reviews. York: University of York; 2001.
229. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 2005;44:813-18.
230. Acott PD, Wong JA, Lang BA, Crocker JFS. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 2005;20:368-73.
231. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43:1960-6.
232. Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991;9 Suppl 6:33-5.
233. Noguera A, Ros JB, Pavia C, Alcover E, Valls C, Villaronga M, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 2003; 16: 529-36.
234. Cimaz R, Gattorno M, Sormani MP, Falcini F, Zulian F, Lepore L, et al. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. J Rheumatol 2002;29:1786-92.
235. Gandrud LM, Cheung JC, Daniels MW, Bachrach LK. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol 2003;16:887-92.
236. Gattinara M, Pontikaki I, Gerloni V, Fantini F. Use of cyclic etidronate in patients with juvenile chronic rheumatic diseases receiving long term treatment with steroids. Ann Rheum Dis 2000;59: 743-4.
237. Bardare M, Grassi A, Dell Era L, Corona F, Bianchi M. Alendronate in the treatment of osteoporosis in rheumatic diseases of childhood. Ann Rheum Dis 2000;59:742.
238. Falcini F, Trapani S, Ermini M, Brandi ML. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 1996;58: 166-9.
239. Brumsen C, Hamdy NAT, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76:266-83.
240. Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000;83:143-5.
241. Bayer M, Stepan J, Kutilek S. Alendronate in treatment of osteoporosis in childhood. Osteologicky Bull 2002;7:23-4.
242. Chlebna-Sokol D, Blaszczyk A, Rusinska A, Loba-Jakubowska E. Treatment of osteoporosis and osteopenia in children - own experience. Przegl Lek 2003;60:5-11.
243. Fernandes JL, Viana SL, Rocha AL, Ribeiro MC, Castro LC. Biphosphonate-induced radiographic changes in two pediatric patients with rheumatic diseases. Skeletal Radiol 2004;33:732-6.
244. Oliveri MB, Palermo R, Mautalen C, Hubscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996;23:2152-5.
245. Warady BD, Lindsley CB, Robinson FG, Lukert BP. Effects of nutritional supplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy. J Rheumatol 1994; 21:530-5.
246. Glorieux FH. Bisphosphonate therapy for severe osteogenesis imperfecta. J Pediatr Endocrinol Metab 2000;13 Suppl 2:989-92.
247. Glorieux FH, Rauch F, Shapiro JR. Bisphosphonates in children with bone diseases. N Engl J Med 2003;349:2068-71.
248. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.
249. Glorieux FH, Travers R, Lanoue G. Pamidronate treatment in children with fibrous dysplasia and osteogenesis imperfecta. Bone 1995; 17:611.
250. Glorieux FH. The use of bisphosphonates in children with osteogenesis, imperfecta. J Pediatr Endocrinol Metab 2001;14 Suppl 6:1491-5.
251. Reed A, Haugen M, Pachman LM, Langman CB. 25-Hydroxyvitamin D therapy in children with active juvenile rheumatoid arthritis: short-term effects on serum osteocalcin levels and bone mineral density. J Pediatr 1991;119:657-60.
252. Hogler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004;145:701-14.
253. van Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 1992;184:249-54.
254. Huzjak N, Barisic I, Resic A, Vrdoljak J, Kusec V, Anticevic D, et al. Our experience in the treatment of osteogenesis imperfecta with bisphosphonates. Paediatria Croatica 2002;46:55-9.
255. Guillot M, Eckart P, Desrosieres H, Amiour M, al Jazayri Z. Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report. Arch Pediat 2001;8:172-5.
256. Giraud F, Meunier PJ. Effect of cyclical intravenous pamidronate theraphy in children with osteogenesis imperfecta. Open-label study in seven patients. Joint Bone Spine 2002;69:486-90.
257. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003;111:573-8.
258. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001;160: 641-4.
259. Bishop NJ, Lanoue G, Chabot G, Travers R, Iorieux FH. Clinical and bone densitometric improvement after pamidronate infusion in children with severe osteogenesis imperfecta. J Bone Miner Res 1996; 11:S251.
260. Sumnik Z, Land C, Rieger-Wettengl G, Korber F, Stabrey A, Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis: a pilot study using radiographic morphometry. Horm Res 2004;61: 137-42.
261. Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004;35:231-4.
262. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis impertecta. Acta Paediatr 1998;87: 64-8.
263. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001;14:529-33.
264. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997;131:622-5.
265. Roldan EJA, Pasqualini T, Plantalech L. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients. J Pediatr Endocrinol Metab 1999;12:555-9.
266. Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004; 19:1742-5.
267. Chien YH, Chu SY, Hsu CC, Hwu WL. Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis 2002;25:593-5.
268. Devogelaer JP, Nagant de Deuxchaisnes C, Malghem J, Maldague B. Cyclical intermittent therapy with APD in a child with osteogenesis imperfecta: a 3-year follow-up of 7 cycles. Evidence of fading away of the oldest radio-opaque bands. In: Christiansen C, Overgaard K, editors. Osteoporosis. Aalborg: Handelstrykkeriet Aalborg, 1990. pp. 1515-17.
269. Huaux JP, Lokietek W. Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 1988;8:71-2.
270. Devogelaer JP, Malghem J, Maldague B, Nagant de Peuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987;16:366-3.
271. Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr 2003;92:452-5.
272. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004;363: 1427-31.
273. Banerjee I, Shortland GJ, Evans WD, Gregory JW. Osteogenesis imperfecta and intravenous pamidronate. Arch Dis Child 2002;87:562-3.
274. Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis-with cyclic sirigle-day intravenous pamidronate infusions. J Pediatr 2003;142:417-23.
275. Astrom E, Soderhalf S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002;86: 356-64.
276. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002;110: 1293-9.
277. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003; 88:986-92.
278. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Mater Res 2004;19:1779-86
279. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2001: 111:1030-6.
280. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003;18: 610-14.
281. Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003;111:e601-3.
282. Grissom LE, Harcke HT. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003;33:226-9.
283. Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices a dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004; 34: 539-46.
284. Robinson RF, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotheraphy 2004;24:195-7.
285. Zacharin M, Baterman J. Pamidronate treatment of osteogenesis imperfecta - lack of correlation, between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002;15: 163-74.
286. Zacharin M, Kanumakala S. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol Metab 2004;17:1511-17.
287. Bin-Abbas BS, Al-Ashwal AA, Al Zayed ZS, Sakati NA. Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta. Saudi Med J 2004;25: 1772-3.
288. DiMeglio LA, Ford I, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004;35:1038-45.
289. Shaw NJ. Bisphosphonates in osteogenesis imperfecta. Arch Dis Child 1997;77:92-3.
290. Ashford RU, Dey A, Kayan K, McCloskey EV, Kanis JA. Oral clodronate as treatment of osteogenesis imperfecta. Arch Dis Child 2003; 88:945.
291. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A. Intravenous pamidronate treatment in Osteogenesis imperfecta. Eur J Pediatr 1998; 157:261-92.
292. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 1997;156:792-4.
293. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85:1846-50.
294. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349:457-63.
295. Ward K, Cowell CT, Little DG. Quantification of metaphyseal modeling in children treated with bisphosphonates. Bone 2005; 36:999-1002.
296. Savage M. Complications with reformulated one-alpha vitamin D. BMJ 2001;322:799.
297. Hoekman K, Papapoulos SE, Peters AC, Bijvoet OL. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 1985;61:952-6.
298. Brenckmann C, Papaioannou A. Bisphosphonates for osteoporosis in people with-cystic fibrosis. Cochrane Database Syst Rev 2006;1-15.
299. Haworth CS, Selby PL, Webb AK, Mawer EB, Adams JE, Freemont TJ. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet 1998;352:1753-4.
300. Cooper C, Dennison EM, Leufkens HG, Bishop N, Van Staa TP. Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res 2004;19: 1976-81.
301. Clark EM, Ness AR, Bishop NJ, Tobias JH. Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 2006;21:1489-95.
302. Van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001;29:517-22.
303. Murray KJ, Boyle RJ, Woo P. Pathological fractures and osteoporosis in a cohort of 103 systemic onset juvenile idiopathic arthritis patients. Arthritis Rheum 2000;43:S119.
304. Maenpaa H, Savolainen A, Lehto MUK, Belt EA. Multiple stress fractures in a young girl with chronic idiopathic arthritis. Extended case report. Joint Bone Spine 2001;68:438-42.
305. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: education and employment. Rheumatology (Oxford) 2002; 41:1436-9.
306. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002;41:1428-35.
307. Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology (Oxford) 2002;41:1444-9.
308. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology (Oxford) 2002;41:1440-3.
309. Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003;48:767-75.
310. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999;10:259-64.
311. Minden K, Niewerth M, Listing J, Biedermann T, Schontube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:836-42.
312. Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol 1992; 19:952-5.
313. Bernatsky S, Duffy, C, Malleson P, Feldman DE, St Pierre V, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum 2007;57:44-8.
314. Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess 2002;6(17).
315. Haapasaari J, Kautiainen HJ, Isomaki HA, Hakala M. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol 2004;31:2286-9.
316. Brunner HI, Barron AC, Graham TB, Passo MH, Johnson AL, Lenihan J, et al. Effects of treatment on costs and health-related quality of life (HRQL) of children with polyarticular course juvenile rheumatoid arthritis (JRA). Arthritis Rheum 2004;50:S686.
317. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098.
318. Lam TK, Leung DT. More on simplified calculation of body-surface area. N Engl J Med 1988;318:1130.
319. Curtis L, Netten A. Unit costs of health and social care. Canterbury: PSSRU, University of Kent; 2005.
320. Epps H, Ginnelly L, Utley M, Southwood T, Gallivan S, Sculpher M, et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess, 2005;9(39).
321. Elliott RA, Davies LM, Payne K, Moore JK, Harper NJ. Costing day case anesthesia: obtaining accurate patient-based costs for adults and children. Int J Technol Assess Health Care 2004;20:552-61.
322. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. URL: http://www.nice.org.uk/pdf/ TAP_Methods.pdf. 2004. Accessed 15 May 2006.
323. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005;90:494-9.
324. Department of Health. National service framework for children, young people and maternity services. London: Department of Health; 2004.
325. Klein GL, Fitzpatrick LA, Langman CB, Beck TJ, Carpenter TO, Gilsanz V, et al. The state of pediatric bone: summary of the ASBMR Pediatric Bone Initiative. J Bone Miner Res 2005;20: 2075-81.
326. Brown JJ, Zacharin MR. Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 2005;41:580-2.
327. Davies UM, Jones J, Reeve J, Camacho-Hubner C, Charlett A, Ansell BM, et al. Juvenile rheumatoid arthritis. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin. Arthritis Rheum 1997;40:332-40.